echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovating the first-line treatment pattern for gastric cancer BMS, Merck, Baekje and other companies are developing in China

    Innovating the first-line treatment pattern for gastric cancer BMS, Merck, Baekje and other companies are developing in China

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On April 19, Bristol-Myers Squibb (BMS) announced that its blockbuster PD-1 inhibitor Opdivo (nivolumab) has become the world's first first-line immunotherapy drug for gastric cancer approved by regulatory agencies.


    In the past few decades, chemotherapy has been the first-line treatment for most patients with advanced gastric cancer.


    BMS: Chinese subgroup results of first-line treatment for gastric cancer have been announced

    BMS: Chinese subgroup results of first-line treatment for gastric cancer have been announced

    Opdivo (Navulimab) developed by BMS is a monoclonal antibody that targets PD-1.


    It is worth mentioning that the pivotal phase 3 study CheckMate-649, which supports the FDA's approval of Opdivo as the first-line treatment of gastric cancer, has also recently announced the results of the Chinese subgroup.


    Merck: Phase 3 clinical trials for HER2-negative gastric cancer are underway

    Merck: Phase 3 clinical trials for HER2-negative gastric cancer are underway

    Keytruda (Pembrolizumab) is a blockbuster PD-1 inhibitor developed by Merck.


    Currently, Merck has launched a randomized, double-blind, global phase 3 clinical trial of KEYNOTE-859 to test the efficacy of Keytruda in combination with chemotherapy in the first-line treatment of patients with HER2-negative advanced gastric cancer.


    BeiGene: Initiated key clinical trials of HER2 dual-antibody in the middle of the year

    BeiGene: Initiated key clinical trials of HER2 dual-antibody in the middle of the year

    ZW25 (zanidatamab) is a bispecific antibody targeting HER2 that BeiGene introduced from Zymeworks in 2018 for more than US$400 million.


    On ASCO-GI in January this year, Zymeworks announced that zanidatamab as a single agent or combined with chemotherapy has achieved positive results in the phase 1 clinical treatment of patients with treated gastroesophageal adenocarcinoma.


    Zai Lab: Initiated Phase 3 Key Study of FGFR2b Monoclonal Anti-Gastric Cancer This Year

    Zai Lab: Initiated Phase 3 Key Study of FGFR2b Monoclonal Anti-Gastric Cancer This Year

    Recently, bemarituzumab, which has been recognized as a breakthrough therapy by the FDA, is a potential "first-in-class" FGFR2b monoclonal antibody developed by Five Prime Therapeutics.


    Previously, bemarituzumab has been combined with chemotherapy in a phase 2 clinical trial for the first-line treatment of patients with advanced gastric cancer or gastroesophageal junction cancer.


    Astellas: CLDN 18.


    Astellas: CLDN 18.


    According to the ClinicalTrials.


    summary

    summary

    Stomach cancer is a common cancer worldwide and an important cause of cancer death.


    Judging from the current global pipeline of first-line treatments for gastric cancer, in addition to PD-1 inhibitors, candidate products such as bispecific antibodies targeting HER2, FGFR2b monoclonal antibodies, and CLDN 18.


    With the approval of Opdivo in the United States, more gastric cancer patients will benefit from innovative therapies in the first-line treatment.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.